

# Carlo Gabriele Tocchetti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/470724/publications.pdf>

Version: 2024-02-01

187  
papers

17,127  
citations

28736

57  
h-index

20023

121  
g-index

204  
all docs

204  
docs citations

204  
times ranked

16914  
citing authors

#	ARTICLE	IF	CITATIONS
1	Direct oral anticoagulants across the heart failure spectrum: the precision medicine era. <i>Heart Failure Reviews</i> , 2022, 27, 135-145.	1.7	2
2	Novel actors on the stage of cardiac dysfunction induced by anti-PD1 oncological treatments. <i>European Heart Journal</i> , 2022, 43, 330-332.	1.0	6
3	Pathophysiology of Takotsubo syndrome – a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology – Part 2: vascular pathophysiology, gender and sex hormones, genetics, chronic cardiovascular problems and clinical implications. <i>European Journal of Heart Failure</i> , 2022, 24, 274-286.	2.9	34
4	Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice. <i>International Journal of Cardiology</i> , 2022, 349, 134-137.	0.8	11
5	Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study. <i>International Journal of Cardiology</i> , 2022, 350, 62-68.	0.8	13
6	Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2022, 24, 406-420.	2.9	22
7	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2022, 118, 3016-3051.	1.8	30
8	Education and certification on heart failure of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 249-253.	2.9	6
9	Cardiovascular events and treatment of children with high risk medulloblastoma. <i>EClinicalMedicine</i> , 2022, 43, 101251.	3.2	1
10	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 4-131.	2.9	820
11	Mitochondrial Creatine Kinase Attenuates Pathologic Remodeling in Heart Failure. <i>Circulation Research</i> , 2022, , CIRCRESAHA121319648.	2.0	6
12	Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan. <i>ESC Heart Failure</i> , 2022, 9, 1107-1117.	1.4	12
13	HNO Protects the Myocardium against Reperfusion Injury, Inhibiting the mPTP Opening via PKC $\mu$ Activation. <i>Antioxidants</i> , 2022, 11, 382.	2.2	6
14	Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 927-943.	2.9	29
15	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. <i>Frontiers in Immunology</i> , 2022, 13, 804597.	2.2	27
16	A PI3K $\beta$ mimetic peptide triggers CFTR gating, bronchodilation, and reduced inflammation in obstructive airway diseases. <i>Science Translational Medicine</i> , 2022, 14, eabl6328.	5.8	6
17	Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients. <i>ESC Heart Failure</i> , 2022, 9, 1666-1676.	1.4	9
18	Janus, or the Inevitable Battle Between Too Much and Too Little Oxygen. <i>Antioxidants and Redox Signaling</i> , 2022, 37, 972-989.	2.5	7

#	ARTICLE	IF	CITATIONS
19	Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 944-958.	2.9	22
20	Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF. <i>ESC Heart Failure</i> , 2022, 9, 2909-2917.	1.4	10
21	Towards standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function. <i>Cardiovascular Research</i> , 2021, 117, 43-59.	1.8	72
22	Cancer Risk in the Heart Failure Population: Epidemiology, Mechanisms, and Clinical Implications. <i>Current Oncology Reports</i> , 2021, 23, 7.	1.8	12
23	Time-weighted lactate as a predictor of adverse outcome in acute heart failure. <i>ESC Heart Failure</i> , 2021, 8, 539-545.	1.4	10
24	Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC). <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 406-415.	0.5	16
25	Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors. <i>Current Oncology Reports</i> , 2021, 23, 13.	1.8	38
26	Metabolic Aspects of Anthracycline Cardiotoxicity. <i>Current Treatment Options in Oncology</i> , 2021, 22, 18.	1.3	48
27	Low-intensity pulsed ultrasound (LIPUS) in heart failure with preserved ejection fraction (HFpEF): <i>lupus in fabula?</i> <i>Cardiovascular Research</i> , 2021, 117, 1238-1240.	1.8	1
28	Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. , 2021, 9, e002007.		36
29	Cardiovascular safety of the tyrosine kinase inhibitor nintedanib. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3690-3698.	1.1	8
30	How can we manage the cardiac toxicity of immune checkpoint inhibitors?. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-10.	1.0	8
31	Noncardiovascular comorbidities in patients with heart failure and their impact on prognosis. <i>Kardiologia Polska</i> , 2021, 79, 493-502.	0.3	3
32	The multifaceted mechanisms of nitroxyl in heart failure: inodilator or “only” vasodilator?. <i>European Journal of Heart Failure</i> , 2021, 23, 1156-1159.	2.9	4
33	New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management. <i>Current Heart Failure Reports</i> , 2021, 18, 191-199.	1.3	5
34	Understanding the heart-brain axis response in COVID-19 patients: A suggestive perspective for therapeutic development. <i>Pharmacological Research</i> , 2021, 168, 105581.	3.1	26
35	Oxidative stress in anticancer therapies-related cardiac dysfunction. <i>Free Radical Biology and Medicine</i> , 2021, 169, 410-415.	1.3	5
36	Current gaps in HFpEF trials: Time to reconsider patients' selection and to target phenotypes. <i>Progress in Cardiovascular Diseases</i> , 2021, 67, 89-97.	1.6	12

#	ARTICLE	IF	CITATIONS
37	Targeting fibrosis in the failing heart with nanoparticles. <i>Advanced Drug Delivery Reviews</i> , 2021, 174, 461-481.	6.6	20
38	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021, 42, 3599-3726.	1.0	5,558
39	Reciprocal organ interactions during heart failure: a position paper from the ESC Working Group on Myocardial Function. <i>Cardiovascular Research</i> , 2021, 117, 2416-2433.	1.8	27
40	<scp>COVID</scp>â€19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1806-1818.	2.9	32
41	Prevention of cancer therapy-related heart failure, is it really possible?. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 441-443.	0.6	1
42	Prognostic impact of diabetes in chronic and acute heart failure. <i>Heart Failure Reviews</i> , 2021, , 1.	1.7	1
43	Metabolic remodelling of glucose, fatty acid and redox pathways in the heart of type 2 diabetic mice. <i>Journal of Physiology</i> , 2020, 598, 1393-1415.	1.3	34
44	Autophagy and cancer therapy cardiotoxicity: From molecular mechanisms to therapeutic opportunities. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020, 1867, 118493.	1.9	27
45	Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure. <i>European Journal of Internal Medicine</i> , 2020, 71, 23-31.	1.0	29
46	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the <scp>Cardioâ€Oncology Study Group</scp> of the <scp>Heart Failure Association</scp> and the <scp>Cardioâ€Oncology Council of the European Society of Cardiology</scp>. <i>European Journal of Heart Failure</i> , 2020, 22, 1966-1983.	2.9	184
47	Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2020, 116, 1820-1834.	1.8	51
48	Redox Imbalances in Ageing and Metabolic Alterations: Implications in Cancer and Cardiac Diseases. An Overview from the Working Group of Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology (SIC). <i>Antioxidants</i> , 2020, 9, 641.	2.2	23
49	Sexâ€related differences in COVIDâ€19 lethality. <i>British Journal of Pharmacology</i> , 2020, 177, 4375-4385.	2.7	69
50	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). <i>European Journal of Heart Failure</i> , 2020, 22, 2272-2289.	2.9	92
51	Commentary on â€Functional Improvement After Outpatient Cardiac Rehabilitation in Acute Coronary Syndrome Patients is not Related to Improvement in Left Ventricular Ejection Fractionâ€ High Blood Pressure and Cardiovascular Prevention, 2020, 27, 179-181.	1.0	0
52	Cardiomyocyte ageing and cardioprotection: consensus document from the ESC working groups cell biology of the heart and myocardial function. <i>Cardiovascular Research</i> , 2020, 116, 1835-1849.	1.8	34
53	Stimulating pro-reparative immune responses to prevent adverse cardiac remodelling: consensus document from the joint 2019 meeting of the ESC Working Groups of cellular biology of the heart and myocardial function. <i>Cardiovascular Research</i> , 2020, 116, 1850-1862.	1.8	22
54	Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the <scp>C</scp>ardioâ€O</scp>ncology <scp>S</scp>tudy <scp>G</scp>roup of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology in collaboration with the <scp>I</scp>nternational <scp>C</scp>ardioâ€O</scp>ncology <scp>S</scp>ociety. <i>European Journal of Heart Failure</i> , 2020,	2.9	364

#	ARTICLE	IF	CITATIONS
55	Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Circulation</i> , 2020, 141, 2031-2034.	1.6	142
56	Non-coding RNAs: update on mechanisms and therapeutic targets from the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2020, 116, 1805-1819.	1.8	39
57	Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4430.	1.8	20
58	Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020, 22, 1504-1524.	2.9	234
59	Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib. <i>Heart Failure Reviews</i> , 2020, 25, 447-456.	1.7	15
60	Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. <i>European Heart Journal</i> , 2020, 41, 1733-1743.	1.0	212
61	Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 467-478.	1.2	179
62	Bmi1 inhibitor PTC-209 promotes Chemically-induced Direct Cardiac Reprogramming of cardiac fibroblasts into cardiomyocytes. <i>Scientific Reports</i> , 2020, 10, 7129.	1.6	28
63	Physical vs. multidimensional frailty in older adults with and without heart failure. <i>ESC Heart Failure</i> , 2020, 7, 1371-1380.	1.4	16
64	Adapted recreational football small-sided games improve cardiac capacity, body composition and muscular fitness in patients with type 2 diabetes. <i>Journal of Sports Medicine and Physical Fitness</i> , 2020, 60, 1261-1268.	0.4	2
65	Cardiac sympathetic dysfunction in pulmonary arterial hypertension: lesson from left-sided heart failure. <i>Pulmonary Circulation</i> , 2019, 9, 1-10.	0.8	13
66	Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens. <i>Heart Failure Reviews</i> , 2019, 24, 915-925.	1.7	39
67	Novel Therapeutic Strategies for the Treatment of Chronic Diseases. <i>Current Medicinal Chemistry</i> , 2019, 26, 2788-2790.	1.2	1
68	What Is the Cardiac Impact of Chemotherapy and Subsequent Radiotherapy in Lymphoma Patients?. Antioxidants and Redox Signaling, 2019, 31, 1166-1174.	2.5	21
69	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 272-285.	2.9	182
70	Cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Cardiovascular Research</i> , 2019, 115, 854-868.	1.8	311
71	Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients. <i>Cardiac Failure Review</i> , 2019, 5, 112-118.	1.2	39
72	Modulation of Redox Signaling in Chronic Diseases and Regenerative Medicine. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-4.	1.9	0

#	ARTICLE	IF	CITATIONS
73	Inflammatory, Serological and Vascular Determinants of Cardiovascular Disease in Systemic Lupus Erythematosus Patients. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2154.	1.8	26
74	Mitochondrial Creatine Kinase Attenuates ROS Emission and Improves Myocyte Survival after ROS in the Failing Heart. <i>Biophysical Journal</i> , 2019, 116, 156a.	0.2	0
75	The novel butyrate derivative phenylalanine- $\beta$ -butyramide protects from doxorubicin-induced cardiotoxicity. <i>European Journal of Heart Failure</i> , 2019, 21, 519-528.	2.9	80
76	Nitroxyl (HNO) targets phospholamban cysteines 41 and 46 to enhance cardiac function. <i>Journal of General Physiology</i> , 2019, 151, 758-770.	0.9	26
77	The continuous heart failure spectrum: moving beyond an ejection fraction classification. <i>European Heart Journal</i> , 2019, 40, 2155-2163.	1.0	195
78	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. , 2019, 7, 53.		59
79	Recent advances in cardio-oncology: a report from the $\sim$ Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019 $\hat{a}$ ™. <i>ESC Heart Failure</i> , 2019, 6, 1140-1148.	1.4	34
80	Permanent atrial fibrillation and pulmonary embolism in elderly patients without deep vein thrombosis: is there a relationship?. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 1121-1128.	1.4	8
81	Treatments targeting inotropy. <i>European Heart Journal</i> , 2019, 40, 3626-3644.	1.0	123
82	Pulmonary Hypertension Induced by Anticancer Drugs. <i>Current Clinical Pathology</i> , 2019, , 133-139.	0.0	1
83	From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. <i>Antioxidants and Redox Signaling</i> , 2019, 30, 2110-2153.	2.5	96
84	Mechanisms of Cardiovascular Damage Induced by Traditional Chemotherapy. <i>Current Clinical Pathology</i> , 2019, , 3-14.	0.0	0
85	Molecular Mechanisms of Cardiovascular Damage Induced by Anti-HER-2 Therapies. <i>Current Clinical Pathology</i> , 2019, , 15-19.	0.0	0
86	Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. <i>European Journal of Heart Failure</i> , 2018, 20, 879-887.	2.9	138
87	Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors, and clinical impact. <i>Pulmonary Circulation</i> , 2018, 8, 1-8.	0.8	43
88	The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. <i>European Journal of Heart Failure</i> , 2018, 20, 445-459.	2.9	118
89	Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth. <i>Circulation</i> , 2018, 138, 696-711.	1.6	145
90	Cardiac Toxicity in Patients Treated With Immune Checkpoint Inhibitors. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1765-1767.	1.2	49

#	ARTICLE	IF	CITATIONS
91	Severe Aortic Valve Regurgitation in Relapsing Polychondritis. <i>Journal of Clinical Rheumatology</i> , 2018, 24, 109-111.	0.5	1
92	An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 216-227.	2.9	81
93	Pharmacovigilating cardiotoxicity of immune checkpoint inhibitors. <i>Lancet Oncology</i> , The, 2018, 19, 1545-1546.	5.1	16
94	Novel Therapeutic Approaches and Targets for the Treatment of Cardiovascular and Immunological Diseases. <i>Current Pharmaceutical Biotechnology</i> , 2018, 19, 684-685.	0.9	0
95	Modern day cardio-oncology: a report from the Heart Failure and World Congress on Acute Heart Failure 2018™. <i>ESC Heart Failure</i> , 2018, 5, 1083-1091.	1.4	23
96	Right heart dysfunction. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 613-623.	0.6	10
97	Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. <i>Cardiovascular Research</i> , 2018, 114, 1287-1303.	1.8	91
98	Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production. <i>Frontiers in Physiology</i> , 2018, 9, 38.	1.3	36
99	Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. <i>Frontiers in Physiology</i> , 2018, 9, 167.	1.3	118
100	Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. <i>Cardiovascular Research</i> , 2018, 114, 1273-1280.	1.8	64
101	Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. <i>Current Medicinal Chemistry</i> , 2018, 25, 1327-1339.	1.2	99
102	Allele-specific differences in transcriptome, miRNome, and mitochondrial function in two hypertrophic cardiomyopathy mouse models. <i>JCI Insight</i> , 2018, 3, .	2.3	33
103	Intracardiac metastasis originated from chondrosarcoma. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 385-388.	0.6	4
104	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2017, 19, 1361-1378.	2.9	115
105	Cardiac Toxicity of Immune Checkpoint Inhibitors. <i>Circulation</i> , 2017, 136, 1989-1992.	1.6	83
106	Cardiotoxicity of immune checkpoint inhibitors. <i>ESMO Open</i> , 2017, 2, e000247.	2.0	186
107	Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond. <i>International Journal of Cardiology</i> , 2017, 227, 11-17.	0.8	64
108	Nanotechnology-Based Cardiac Targeting and Direct Cardiac Reprogramming: The Betrothed. <i>Stem Cells International</i> , 2017, 2017, 1-12.	1.2	22



#	ARTICLE	IF	CITATIONS
109	The Influence of Fiber on Gut Microbiota: Butyrate as Molecular Player Involved in the Beneficial Interplay Between Dietary Fiber and Cardiovascular Health. , 2017, , 61-71.		4
110	Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions – A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of Cardiology. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-13.	1.9	10
111	Pathophysiology of anthracycline cardiotoxicity. Journal of Cardiovascular Medicine, 2016, 17, e3-e11.	0.6	31
112	Role of biomarkers in monitoring antitumor cardiotoxicity. Journal of Cardiovascular Medicine, 2016, 17, e27-e34.	0.6	18
113	A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity. Journal of Cardiovascular Medicine, 2016, 17, e84-e92.	0.6	47
114	A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity. Journal of Cardiovascular Medicine, 2016, 17, e93-e104.	0.6	37
115	Cardiovascular imaging in the diagnosis and monitoring of cardiotoxicity. Journal of Cardiovascular Medicine, 2016, 17, e35-e44.	0.6	20
116	Cardiac Over-Expression of Creatine Kinase Differentially Affects Cardiomyocyte Function in Ischemic and Non-Ischemic Heart Failure. Biophysical Journal, 2016, 110, 599a.	0.2	0
117	Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs. Journal of Cardiac Failure, 2016, 22, 449-458.	0.7	60
118	Biomarkers in sarcopenia: A multifactorial approach. Experimental Gerontology, 2016, 85, 1-8.	1.2	145
119	Preventing antitumor drug-related cardiomyopathy. Journal of Cardiovascular Medicine, 2016, 17, e64-e75.	0.6	23
120	Current views on anthracycline cardiotoxicity. Heart Failure Reviews, 2016, 21, 621-634.	1.7	39
121	Testosterone Antagonizes Doxorubicin-Induced Senescence of Cardiomyocytes. Journal of the American Heart Association, 2016, 5, .	1.6	62
122	Bidirectional cross-regulation between ErbB2 and $\beta$ -adrenergic signalling pathways. Cardiovascular Research, 2016, 109, 358-373.	1.8	44
123	Cardiac Over-Expression of Creatine Kinase Improves Function in Failing Myocytes. Biophysical Journal, 2015, 108, 595a.	0.2	1
124	Impaired mitochondrial energy supply coupled to increased H <sub>2</sub> O <sub>2</sub> emission under energy/redox stress leads to myocardial dysfunction during Type 2 diabetes. Clinical Science, 2015, 129, 561-574.	1.8	37
125	Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs. BioMed Research International, 2015, 2015, 1-14.	0.9	34
126	Restoring redox balance enhances contractility in heart trabeculae from type 2 diabetic rats exposed to high glucose. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H291-H302.	1.5	42



#	ARTICLE	IF	CITATIONS
127	Protective Mechanisms of Mitochondria and Heart Function in Diabetes. Antioxidants and Redox Signaling, 2015, 22, 1563-1586.	2.5	59
128	Constitutive BDNF/TrkB signaling is required for normal cardiac contraction and relaxation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1880-1885.	3.3	96
129	Cardioprotection by gene therapy. International Journal of Cardiology, 2015, 191, 203-210.	0.8	34
130	Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. Heart Failure Reviews, 2015, 20, 621-631.	1.7	40
131	Nitroso-Redox Balance and Modulation of Basal Myocardial Function: An Update from the Italian Society of Cardiovascular Research (SIRC). Current Drug Targets, 2015, 16, 895-903.	1.0	25
132	Endogenous Cardioprotective Agents: Role in Pre and Postconditioning. Current Drug Targets, 2015, 16, 843-867.	1.0	47
133	Mitral peak early diastolic filling velocity to deceleration time ratio as a predictor of prognosis in patients with chronic heart failure and preserved or reduced ejection fraction. Journal of Geriatric Cardiology, 2015, 12, 346-52.	0.2	4
134	<scp>ESC</scp> Working Group on Myocardial Function Position Paper: how to study the right ventricle in experimental models. European Journal of Heart Failure, 2014, 16, 509-518.	2.9	11
135	Targeting myocardial remodelling to develop novel therapies for heart failure. European Journal of Heart Failure, 2014, 16, 494-508.	2.9	90
136	CCR5 Inhibition Prevents Cardiac Dysfunction in the SIV/Macaque Model of HIV. Journal of the American Heart Association, 2014, 3, e000874.	1.6	25
137	Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. European Journal of Heart Failure, 2014, 16, 358-366.	2.9	76
138	Nitroxyl (HNO) for Treatment of Acute Heart Failure. Current Heart Failure Reports, 2014, 11, 227-235.	1.3	36
139	HNO Enhances SERCA2a Activity and Cardiomyocyte Function by Promoting Redox-Dependent Phospholamban Oligomerization. Antioxidants and Redox Signaling, 2013, 19, 1185-1197.	2.5	74
140	Aldose Reductase Inhibition or Activation of Transketolase Offset Adverse Metabolic Remodeling Improving Function in Type 2 Diabetes Myocytes Exposed to Hyperglycemia. Biophysical Journal, 2013, 104, 159a.	0.2	1
141	Nitroxyl (HNO). Circulation: Heart Failure, 2013, 6, 1250-1258.	1.6	109
142	Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature. Future Oncology, 2013, 9, 127-133.	1.1	2
143	Glutathione oxidation unmasks proarrhythmic vulnerability of chronically hyperglycemic guinea pigs. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 304, H916-H926.	1.5	20
144	The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors. European Journal of Heart Failure, 2013, 15, 482-489.	2.9	61

#	ARTICLE	IF	CITATIONS
145	Utility of 2D-speckle tracking echocardiography in diagnosis of left ventricular dysfunction in anti-ErbB2 therapy.. Journal of Clinical Oncology, 2013, 31, 169-169.	0.8	0
146	Inhibition of cardiomyocytes late INa with ranolazine to prevent anthracyclines cardiotoxicity in experimental models in vitro and in vivo.. Journal of Clinical Oncology, 2013, 31, 170-170.	0.8	0
147	Oxidative and nitrosative stress in the maintenance of myocardial function. Free Radical Biology and Medicine, 2012, 53, 1531-1540.	1.3	85
148	Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. Journal of Molecular and Cellular Cardiology, 2012, 52, 1213-1225.	0.9	1,053
149	GSH or Palmitate Preserves Mitochondrial Energetic/Redox Balance, Preventing Mechanical Dysfunction in Metabolically Challenged Myocytes/Hearts From Type 2 Diabetic Mice. Diabetes, 2012, 61, 3094-3105.	0.3	77
150	Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. European Journal of Heart Failure, 2012, 14, 130-137.	2.9	77
151	Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. Breast Cancer Research and Treatment, 2012, 133, 511-521.	1.1	43
152	Le alterazioni elettrocardiografiche espressione di cardiotossicit�. Journal of Cardiovascular Echography, 2011, 21, 55-59.	0.1	0
153	Early Identification of Left Ventricular Dysfunction Induced by Trastuzumab. Journal of the American College of Cardiology, 2011, 58, 2698-2699.	1.2	3
154	1114 POSTER The Anticancer MTOR-inhibitor Temsirolimus Induces Cardiotoxicity in a Mouse Model. European Journal of Cancer, 2011, 47, S128.	1.3	0
155	P114 The anti-neoplastic ErbB2-antibody 2C4 produces left ventricular dysfunction in murine hearts. Breast, 2011, 20, S20.	0.9	0
156	Complete atrioventricular block in a patient with intracardiac metastases from malignant melanoma. European Heart Journal Cardiovascular Imaging, 2011, 12, 636-636.	0.5	2
157	Playing with Cardiac "Redox Switches": The "HNO Way" to Modulate Cardiac Function. Antioxidants and Redox Signaling, 2011, 14, 1687-1698.	2.5	101
158	Early detection of cardiac dysfunction induced by the mTOR inhibitor temsirolimus.. Journal of Clinical Oncology, 2011, 29, e13612-e13612.	0.8	0
159	The ErbB2-antibody 2C4 and cardiac dysfunction in mice.. Journal of Clinical Oncology, 2011, 29, e11040-e11040.	0.8	0
160	PDE5A suppression of acute $\beta$ -adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation. Basic Research in Cardiology, 2010, 105, 337-347.	2.5	92
161	Nitroxyl enhances myocyte Ca <sup>2+</sup> transients by exclusively targeting SR Ca <sup>2+</sup> -cycling. Frontiers in Bioscience - Elite, 2010, E2, 614-626.	0.9	36
162	Prognostic Significance of Left Atrial Volume Dilatation in Patients with Hypertrophic Cardiomyopathy. Journal of the American Society of Echocardiography, 2009, 22, 76-81.	1.2	75

#	ARTICLE	IF	CITATIONS
163	Phospholamban Thiols Play a Central Role in Activation of the Cardiac Muscle Sarcoplasmic Reticulum Calcium Pump by Nitroxyl. <i>Biochemistry</i> , 2008, 47, 13150-13152.	1.2	91
164	Reversal of Cardiac Hypertrophy and Fibrosis From Pressure Overload by Tetrahydrobiopterin. <i>Circulation</i> , 2008, 117, 2626-2636.	1.6	223
165	Compartmentalization of Cardiac $\hat{I}^2$ -Adrenergic Inotropy Modulation by Phosphodiesterase Type 5. <i>Circulation</i> , 2007, 115, 2159-2167.	1.6	151
166	Nitroxyl Improves Cellular Heart Function by Directly Enhancing Cardiac Sarcoplasmic Reticulum Ca <sup>2+</sup> Cycling. <i>Circulation Research</i> , 2007, 100, 96-104.	2.0	209
167	Nitroxyl increases force development in rat cardiac muscle. <i>Journal of Physiology</i> , 2007, 580, 951-960.	1.3	89
168	The pharmacology of nitroxyl (HNO) and its therapeutic potential: Not just the janus face of NO11This review is dedicated to the career of Prof. Herbert T. Nagasawa, a pioneer in the field of HNO chemistry, biochemistry and pharmacology.., 2007, 113, 442-458.		222
169	The Activation of Metabolites of Nitric Oxide Synthase by Metals Is Both Redox and Oxygen Dependent: A New Feature of Nitrogen Oxide Signaling. <i>Antioxidants and Redox Signaling</i> , 2006, 8, 1363-1371.	2.5	27
170	Discriminating formation of HNO from other reactive nitrogen oxide species. <i>Free Radical Biology and Medicine</i> , 2006, 40, 1056-1066.	1.3	99
171	Peroxynitrite and myocardial contractility: In vivo versus in vitro effects. <i>Free Radical Biology and Medicine</i> , 2006, 41, 1606-1618.	1.3	53
172	Compartmentalized Phosphodiesterase-2 Activity Blunts $\hat{I}^2$ -Adrenergic Cardiac Inotropy via an NO/cGMP-Dependent Pathway. <i>Circulation Research</i> , 2006, 98, 226-234.	2.0	252
173	Metalloproteinase Inhibitor Counters High-Energy Phosphate Depletion and AMP Deaminase Activity Enhancing Ventricular Diastolic Compliance in Subacute Heart Failure. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 506-513.	1.3	30
174	Comparison of the Chemical Biology of NO and HNO: An Inorganic Perspective. <i>Progress in Inorganic Chemistry</i> , 2005, , 349-384.	3.0	11
175	Comparison of the NO and HNO Donating Properties of Diazeniumdiolates: Primary Amine Adducts Release HNO in Vivo. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 8220-8228.	2.9	118
176	Calcitonin Gene-Related Peptide In Vivo Positive Inotropy Is Attributable to Regional Sympatho-Stimulation and Is Blunted in Congestive Heart Failure. <i>Circulation Research</i> , 2005, 96, 234-243.	2.0	58
177	Mechanism of Aerobic Decomposition of Angeli's Salt (Sodium Trioxodinitrate) at Physiological pH. <i>Journal of the American Chemical Society</i> , 2005, 127, 722-731.	6.6	105
178	The Chemical Dynamics of NO and Reactive Nitrogen Oxides: A Practical Guide. <i>Current Molecular Medicine</i> , 2004, 4, 723-740.	0.6	41
179	Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy. <i>American Journal of Cardiology</i> , 2004, 94, 895-900.	0.7	114
180	Hemodynamic effects of isometric exercise in hypertrophic cardiomyopathy: Comparison with normal subjects. <i>Journal of Nuclear Cardiology</i> , 2003, 10, 154-160.	1.4	9

#	ARTICLE	IF	CITATIONS
181	Myocardial Collagen Turnover in Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2003, 108, 1455-1460.	1.6	185
182	Dobutamine Stress Echocardiography in Hypertrophic Cardiomyopathy. <i>Cardiology</i> , 2003, 100, 93-100.	0.6	11
183	Comparison of hemodynamic adaptation to orthostatic stress in patients with hypertrophic cardiomyopathy with or without syncope and in vasovagal syncope. <i>American Journal of Cardiology</i> , 2002, 89, 1405-1410.	0.7	17
184	Determinants and clinical significance of natriuretic peptides and hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2001, 22, 1328-1336.	1.0	58
185	PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus. <i>EMBO Journal</i> , 1998, 17, 3858-3866.	3.5	157
186	Abnormal glucose transport and GLUT1 cell-surface content in fibroblasts and skeletal muscle from NIDDM and obese subjects. <i>Diabetologia</i> , 1997, 40, 421-429.	2.9	36
187	O-51: Overexpression of the MAT-1 oncogene in non-insulin-dependent diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1996, 104, 63-63.	0.6	0